October 06, 2011 08:15 ET

Equity Research on Gilead Sciences Inc. and Human Genome Sciences Inc. - Regulatory Approval Key for Biotech Companies

NEW YORK, NY--(Marketwire - Oct 6, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on Gilead Sciences Inc. (NASDAQ: GILD) and Human Genome Sciences Inc. (NASDAQ: HGSI). Register with us today at to have free access to these research reports.

Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. Get your free reports on Gilead Sciences Inc. and Human Genome Sciences Inc. at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Gilead Sciences Inc. and Human Genome Sciences Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency gave a positive recommendation for Eviplera, a combination of Gilead Sciences Inc.'s Truvada and Johnson and Johnson's Edurant, for the treatment of HIV in previously untreated adults. The recommendation bodes very well for European approval when the EMA will make its decision later in the year. Gilead Sciences Inc. report is accessible for free by registering today at

Human Genome Sciences Inc. has not been as fortunate recently. British regulators chose not to approve the company's lupus drug, Benylsta, for national coverage. The drug had previously seen positive sales in the U.S. though. Human Genome Sciences Inc. report is accessible for free by registering today at

Overall, investors appear particularly sensitive to regulatory decisions on new drugs. Companies receiving approvals could see share prices climb while negative decisions may do just the opposite.

The two Biotechnology stocks research reports are available for free by signing up now on


Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information